L 372460
Latest Information Update: 15 Aug 2002
Price :
$50 *
At a glance
- Originator Merck & Co
- Class Antithrombotics; Pyrrolidines
- Mechanism of Action Thrombin inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Thrombosis
Most Recent Events
- 03 Aug 1998 New profile
- 03 Aug 1998 Preclinical development for Thrombosis in USA (Unknown route)